-
Uncategorized2 weeks agoLilly dives into vaccine research with 3 biotech buyouts
Worth close to $4 billion combined, the acquisitions of Curevo, Limmatech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio. Read More
-
Uncategorized2 weeks ago
Olympus pushes deeper into oncology with $270M BioProtect deal
Olympus is pushing deeper into prostate cancer care with the acquisition of BioProtect, an Israeli company whose biodegradable balloon spacer has been used in more than...
-
Uncategorized2 weeks agoSLAS reveals New Product Awards winners
SLAS has revealed the winners of its New Product Awards, drawing the Vienna conference to a close. Among the winners are Bionomous for its Sortivo technology, a next-generation large-particle sorter,...
-
Uncategorized2 weeks ago
MOSAIC: Multimodal In Vivo Imaging Data Powers AI Models for Living Systems
MOSAIC: Multimodal In Vivo Imaging Data Powers AI Models for Living Systems
-
Uncategorized2 weeks agoTrump is seeing doctors for his annual physical. What the public finds out is up to him
WASHINGTON — President Donald Trump is getting a medical exam on Tuesday, putting his health under renewed public scrutiny after he has worked to dismiss concerns over his age and stamina. The...
-
Uncategorized2 weeks agoSTAT+: Five biotech news updates to stay on top of today
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hi! Hope you had a...
-
Uncategorized2 weeks ago
Lilly lands vaccine trifecta with 3 new biotech buys valued at up to $3.8B
Eli Lilly, with a busier-than-ever business development team, has made a major vaccine play‚ months after hiring veteran vaccine regulator Peter Marks following his FDA departure.
-
Uncategorized2 weeks ago
Lilly is pharma’s top dog, placing first in innovation and invention: IDEA
Lilly is pharma’s top dog, placing first in innovation and invention: IDEA
-
Uncategorized2 weeks agoSTAT+: Eli Lilly to buy three small vaccine developers
Eli Lilly said Tuesday it would buy three early- and mid-stage vaccine developers, a boost for the field. The deals — which together could cost up...
-
Uncategorized2 weeks ago
Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study
A single 1-mg/kg dose of Eli Lilly’s base editor can lower LDL cholesterol levels by 62% in patients with a heritable form of hypercholesterolemia. The pharma...
STAT+: At hospital finance conference, a call to end the friction that’s keeping costs high
Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks
